Arun H Shastry1, Balaram Thota2, Mallavarapu R Srividya2, Arimappamagan Arivazhagan3, Vani Santosh4,5. 1. Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, India. 2. Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, India. 3. Department of Neurosurgery, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, India. 4. Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, India. vani.santosh@gmail.com. 5. Department of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, India. vani.santosh@gmail.com.
Abstract
BACKGROUND: Protein phosphatase 1 α (PP1A) is an enzyme intimately associated with cell cycle, the over expression of which has been demonstrated in glioblastoma (GBM). Further, the nuclear expression of PP1A has been shown to be highly specific to GBM. In addition, PP1A has been shown to be a connecting molecule in the p53 containing GBM sub network. In view of these, we evaluated the prognostic relevance of PP1A. METHODS: GBM tissues were examined for protein expression of PP1A by immunohistochemistry (IHC). Nuclear expression of PP1A was scored in all tumor tissue samples. Survival analyses were performed by Cox-Regression and Kaplan-Meier survival analysis with Log Rank tests. IDH1, ATRX and p53 IHC and stratification of all GBM cases were performed and subgroup specific evaluation of nuclear PP1A correlation with overall and progression free survival was performed. RESULTS: PP1A protein expression showed no correlation with prognosis in all cases of GBM or on stratification based on IDH1 or ATRX expression. However on p53 stratification nuclear PP1A expression emerged as strong independent predictor of poor overall survival only in p53 positive GBMs both in univariate and multivariate analysis. CONCLUSIONS: While PP1A expression uniquely associates with poor prognosis only in p53 expressing GBMs, there is a notable absence of such correlation in p53 negative GBMs; thus skewing the overall relation of this molecule with prognosis in GBM. PP1A emerging as a strong prognostic marker in p53 expressing GBMs, enables us to foresee this molecule as a potential therapeutic target.
BACKGROUND: Protein phosphatase 1 α (PP1A) is an enzyme intimately associated with cell cycle, the over expression of which has been demonstrated in glioblastoma (GBM). Further, the nuclear expression of PP1A has been shown to be highly specific to GBM. In addition, PP1A has been shown to be a connecting molecule in the p53 containing GBM sub network. In view of these, we evaluated the prognostic relevance of PP1A. METHODS: GBM tissues were examined for protein expression of PP1A by immunohistochemistry (IHC). Nuclear expression of PP1A was scored in all tumor tissue samples. Survival analyses were performed by Cox-Regression and Kaplan-Meier survival analysis with Log Rank tests. IDH1, ATRX and p53 IHC and stratification of all GBM cases were performed and subgroup specific evaluation of nuclear PP1A correlation with overall and progression free survival was performed. RESULTS:PP1A protein expression showed no correlation with prognosis in all cases of GBM or on stratification based on IDH1 or ATRX expression. However on p53 stratification nuclear PP1A expression emerged as strong independent predictor of poor overall survival only in p53 positive GBMs both in univariate and multivariate analysis. CONCLUSIONS: While PP1A expression uniquely associates with poor prognosis only in p53 expressing GBMs, there is a notable absence of such correlation in p53 negative GBMs; thus skewing the overall relation of this molecule with prognosis in GBM. PP1A emerging as a strong prognostic marker in p53 expressing GBMs, enables us to foresee this molecule as a potential therapeutic target.
Entities:
Keywords:
Glioblastoma; PPP1CA; Prognosis; Protein phosphatase 1 α; TP53
Authors: Sreekanth P Reddy; Ramona Britto; Katyayni Vinnakota; Hebbar Aparna; Hari Kishore Sreepathi; Balaram Thota; Arpana Kumari; B M Shilpa; M Vrinda; Srikantha Umesh; Cini Samuel; Mitesh Shetty; Ashwani Tandon; Paritosh Pandey; Sridevi Hegde; A S Hegde; Anandh Balasubramaniam; B A Chandramouli; Vani Santosh; Paturu Kondaiah; Kumaravel Somasundaram; M R Satyanarayana Rao Journal: Clin Cancer Res Date: 2008-05-15 Impact factor: 12.531
Authors: Michael Weller; Jörg Felsberg; Christian Hartmann; Hilmar Berger; Joachim P Steinbach; Johannes Schramm; Manfred Westphal; Gabriele Schackert; Matthias Simon; Jörg C Tonn; Oliver Heese; Dietmar Krex; Guido Nikkhah; Torsten Pietsch; Otmar Wiestler; Guido Reifenberger; Andreas von Deimling; Markus Loeffler Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Eva M Verdugo-Sivianes; Lola Navas; Sonia Molina-Pinelo; Irene Ferrer; Alvaro Quintanal-Villalonga; Javier Peinado; Jose M Garcia-Heredia; Blanca Felipe-Abrio; Sandra Muñoz-Galvan; Juan J Marin; Luis Montuenga; Luis Paz-Ares; Amancio Carnero Journal: Oncotarget Date: 2017-10-26
Authors: Stewart G Martin; Siwei Zhang; Song Yang; Behnaz Saidy; Suha Deen; Sarah J Storr Journal: J Cell Mol Med Date: 2020-06-25 Impact factor: 5.310